• Save
Latest Oncologic Strategies For Well Differentiated Thyroid Carcinoma
Upcoming SlideShare
Loading in...5
×
 

Latest Oncologic Strategies For Well Differentiated Thyroid Carcinoma

on

  • 3,403 views

 

Statistics

Views

Total Views
3,403
Views on SlideShare
3,359
Embed Views
44

Actions

Likes
3
Downloads
0
Comments
1

3 Embeds 44

http://www.u-surgery.com 26
http://www.slideshare.net 15
http://u-surgery.com 3

Accessibility

Categories

Upload Details

Uploaded via as Adobe PDF

Usage Rights

© All Rights Reserved

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Processing…
  • thank you
    Are you sure you want to
    Your message goes here
    Processing…
Post Comment
Edit your comment

Latest Oncologic Strategies For Well Differentiated Thyroid Carcinoma Latest Oncologic Strategies For Well Differentiated Thyroid Carcinoma Presentation Transcript

  • Latest Oncologic Strategies for Well-Differentiated Thyroid Carcinoma April 2008 Michael W. Yeh, MD Program Director, Endocrine Surgery Assistant Professor of Surgery and Medicine David Geffen School of Medicine at UCLA www.endocrinesurgery.ucla.edu
  • Case #1 • 22 yo F biology student • 2.5 cm right thyroid nodule • Euthyroid • FNA: “Sheets of follicular cells forming papillary structures, abundant nuclear grooves and intranuclear inclusions” • Further workup necessary? • What is the most appropriate operation?
  • Surgeon-performed ultrasound
  • New plan? • Total thyroidectomy • Central (bilateral level 6) lymph node dissection • Right modified radical neck dissection
  • Learning objectives • Focus on papillary thyroid carcinoma • Extent of initial surgery for PTC • Is there a role for initial “prophylactic” lymph node dissection? • Importance of ultrasound in initial staging • Limitations of radioiodine therapy • Impact of initial surgery on outcome and subsequent surveillance • Surgeon’s role in management of PTC recurrences
  • Thyroid cancer incidence is driven by PTC Davies L, Increasing incidence of thyroid cancer in the United States, 1973-2002, JAMA 2006.
  • Survival and Recurrence in PTC Bilimoria K, Extent of surgery affects survival for papillary thyroid cancer, Ann Surg 2007
  • Timing of Recurrences in PTC Mazzaferri E, Current approaches to primary therapy for papillary and follicular thyroid cancer, J Clin Endo Metab 2001
  • Prevalence of lymph node mets in PTC Ito Y, Clinical significance of lymph node metastasis of thyroid papillary carcinoma located in one lobe, World J Surg, 2006
  • Prevalence of lymph node mets in PTC 30% Gimm O, Pattern of lymph node metastases in papillary thyroid carcinoma, Br J 4% 45% Surg 1998
  • • Up to 39% of re-operations for thyroid cancer are a direct result of incomplete initial surgery Kouvaraki, Preventable reoperations for persistent and recurrent papillary thyroid carcinoma, Surgery 2004
  • What we know thus far • PTC is increasingly common • Survival remains excellent • PTC <1 cm is not associated with cause-specific death • Recurrences are common (30%) • Most recurrences occur within 10 yrs of initial dx • These are generally locoregional lymph node mets • “Recurrences” may actually represent persistent disease • Microscopic lymph node metastases of PTC are the rule • Only a small fraction (1/4-1/3) of these go on to become clinically significant • Most micrometastases remain quiescent!
  • What is the impact of PTC nodal mets? • Conventional wisdom: No clinical impact (survival) • Swedish study examining 5123 cases of DTC Cady B, Papillary carcinoma of the thyroid gland: Treatment based on risk group definition; Surg Oncol Clin N Am, 1998 Lundgren C, Clinically significant prognostic factors in differentiated thyroid carcinoma, Cancer 2005
  • What is the impact of PTC nodal mets? “We found a 4-fold risk of recurrence and a 2.5-fold risk of cancer-specific death in patients with regional lymph node metastases.” Loh K, Pathological tumor-node- metastasis staging for papillary and follicular thyroid carcinomas: A retrospective analysis of 700 patients, J Clin Endo Metab 1997
  • Surgeon’s role in optimizing PTC care • Management over the life span • Prevent recurrences: survival impact, cost, risk of re- operation, emotional toll • Make a personal investment in long term outcome • Partner with the endocrinologist, esp. in high risk patients
  • Surgeon’s role in optimizing PTC care • For PTC >1 cm • Total thyroidectomy: multifocality, give RAI, follow Tg • Clear all palpable adenopathy at initial surgery • Clear all sonographically detectable adenopathy at initial surgery • Surgeon’s responsibility to obtain high-quality pre-op US node survey for all FNA+ PTC and have a working knowledge of the “lay of the land” • “Prophylactic” initial lymph node dissection?? • Concept of compartment-oriented lymph node dissection
  • 2006 ATA guidelines R27. Routine central-compartment (level VI) neck dissection should be considered for patients with papillary thyroid carcinoma and suspected Hürthle carcinoma. Near-total or total thyroidectomy without central node dissection may be appropriate for follicular cancer, and when followed by radioactive iodine therapy, may provide an alternative approach for papillary and Hürthle cell cancers—Recommendation B The American Thyroid Association Guidelines Taskforce, Management guidelines for patients with thyroid nodules and differentiated thyroid cancer, Thyroid 2006
  • Support for initial CND in PTC • Goteborg study: 195 PTC patients studied prospectively • Mean f/u 13 yrs • Routine, meticulous bilateral central neck clearance • RAI used sparingly • Much lower CSM compared to controls Tissell L, Improved survival of patients with papillary thyroid cancer after surgical microdissection, World J Surg 1996 REVIEWED IN: White M, Central lymph node dissection in differentiated thyroid cancer, World J Surg 2007
  • • Hannnover study: 342 pts, mean f/u 11.8 yrs • Central compartment microdissection reduces CSM and recurrence Scheumann G, Prognostic significance and surgical management of locoregional lymph node metastases in papillary thyroid cancer, World J Surg 1994
  • • Sydney study: 447 pts with PTC >1 cm and clinically negative nodes • 56 underwent ipsilateral CND (2002 and beyond) • Mean post-op, post-RAI serum Tg lower in CND group • Post-op, post-RAI serum Tg more likely to be undetectable in CND group Sywak M, Routine ipsilateral level 6 lymphadenectomy reduces postoperative thyroglobulin levels in papillary thyroid cancer, Surgery 2006
  • CND: Technique
  • CND: Technique and complications • Territory bounded by hyoid and thoracic inlet, both jugular veins • Majority of yield is in triangular space bounded by midline, RLN, innominate vessels • Routine auto-transplantation of inferior parathyroid • Ipsilateral CND is generally sufficient – no additional benefit to bilateral in terms of post-op Tg • Permanent hypoparathyroidism 1.4-14.3% (3.1%) • Permanent RLN paresis 0-4.2% (0.5%) • Temporary RLN dysfunction may be higher • No difference in long-term complication rate when performed by expert/high-volume surgeons
  • Radio-iodine: Myth and reality • Conventional wisdom: “Mops up” residual disease after surgery • Truth: Ineffective in treatment of macroscopic (incl. sonographically detectable) remnants and nodal disease • Post-op RAI is given only for ablation of residual normal thyroid tissue (set Tg to zero) • Even this is likely unnecessary after true TTx • RAI is no substitute for excellent surgery Hay I, Managing patients with papillary thyroid carcinoma: Insights gained from the Mayo Clinic’s experience of treated 2,512 consecutive patients during 1940 through 2000, Trans Am Clin Climatol Assoc, 2002
  • Radioiodine and lymph node mets of PTC • Primary tumors have reduced ability to take up RAI compared to normal thyroid • 25% of WDTC are initially resistant to RAI • Many nodal mets of PTC do not express NIS • RAI has no effect on nodal mets >1 cm in diameter • Likely has no effect on nodal mets of any size Clark O, Textbook of endocrine surgery, Elsevier Saunders 2005
  • Case: Radioiodine misuse • 22F Dx 2.0 cm right PTC • Total thyroidectomy in 2004 • Post-op RAI 50 mCi • 2005 surveillance scan shows uptake in low central neck • Treatment dose given, 150 mCi RAI • 2006 surveillance scan shows uptake in low central neck • Treatment dose given, 200 mCi RAI • Tg 10.3 ng/mL after thyroxine withdrawal • Next step?
  • Case: Radioiodine misuse • FNA right level 3 lymph node + metastatic PTC • Undergoes right modified radical neck dissection (levels 2, 3, 4) and right central neck dissection (level 6) • Path: Right levels 2, 3, 4 – 1/11 lymph nodes positive Right level 6 – 1/1 lymph node positive • No further RAI treatment • Post-op US negative • Post-op Tg undetectable • No effect of cumulative dose 400 mCi RAI on two subcentimeter lymph nodes!
  • Surgery vs Radioiodine • Most PTC patients are low risk (MACIS score <6) • For patients undergoing complete initial surgical clearance, RAI confers no additional benefit • For patients who do not have complete initial surgical clearance, no amount of post-op RAI will improve the situation – these patients need further surgery • RAI benefits a small subset of high-risk PTC patients • Works reasonably well for pulmonary metastases • No impact on lymph node disease
  • Hay I, Managing patients with papillary thyroid carcinoma: Insights gained from the Mayo Clinic’s experience of treated 2,512 consecutive patients during 1940 through 2000, Trans Am Clin Climatol Assoc, 2002
  • Case: Piecework • 34F Dx 2.5 cm right PTC in 1998 • Op #1: Open bx right neck lymph node • Op #2: Total thyroidectomy, lymph node sampling (+) • Op #3: Take back for bleeding. Disease recurs. • Permanent hypoparathyroidism • Op #4: Right neck dissection. Disease recurs. • Op #5: Re-do right neck dissection. Disease recurs. • 2001-2006: Tg elevated (144.6 ng/mL stimulated), multiple CTs, PET scans, MRIs all inconclusive • Tg was never satisfactorily low • May 2006 pt seeks care at UCLA
  • Case: Piecework • Op #6: Re-do right level 2 clearance • Op #7: Re-do right level 6 clearance • Path: 3 of 9 nodes positive in level 2, and 3 of 4 nodes positive in level 6 • Post-op Tg 2.0 ng/mL • 7 operations over 10 years • Countless labs, scans, procedures • Acute on chronic disability • Cost RE lost productivity, health care $$? • QOL? • Importance of compartment-oriented surgery
  • Case: Missing ultrasound • 71M with 1.5 cm right thyroid mass • FNA: Follicular neoplasm • Plan right thyroid lobectomy • Pt in OR under anesthetic
  • Ultrasound • Essential for all surgeons interested in treating thyroid cancer • Competent ≠ FLUENT • Certification courses available through ACS: basic, head & neck, instructors course • Make it a part of your daily practice: clinic & OR • Many available platforms: Sonosite, GE, Terason • Probes: 9-14 MHz linear array
  • Summary points • Ultrasound is essential: EVERY cancer case • Clear the neck of disease • Do it right the first time around • When you enter a nodal compartment, commit to clearing it completely • No role for “node picking” • Consider routine initial “prophylactic” ipsilateral central (level 6) lymph node dissection for FNA positive PTC >1 cm in diameter • Have appropriately low expectations for what RAI can do • Be vigilant for recurrences: surveillance US and Tg